Salutaris Medical Devices

Salutaris Medical Devices

Medical Devices, Tucson, Arizona, United States, 1-10 Employees

  • LinkedIn

phone no Phone Number: 15*********


About Salutaris Medical Devices, Inc (SalutarisMD) SalutarisMD is a pre-revenue medical device company founded to engineer a novel ophthalmic treatment for Wet age-related Macular Degener...

Read More


industries-icon Industry: Medical Devices

SIC SIC Code: 3841 | NAICS Code: 339112 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SALUTARIS MEDICAL DEVICES

Salutaris Medical Devices Org Chart and Mapping


Ryan Lohrenz

Chief Operating Officer

Mary Drew

Director of Clinical Operations

You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Salutaris Medical Devices

Answer: Salutaris Medical Devices's headquarters are located at Tucson, Arizona, United States

Answer: Salutaris Medical Devices's phone number is 15*********

Answer: Salutaris Medical Devices's official website is

Answer: Salutaris Medical Devices's revenue is $1 Million to $5 Million

Answer: Salutaris Medical Devices's SIC: 3841

Answer: Salutaris Medical Devices's NAICS: 339112

Answer: Salutaris Medical Devices has 1-10 employees

Answer: Salutaris Medical Devices is in Medical Devices

Answer: Salutaris Medical Devices contact info: Phone number: 15********* Website:

Answer: About Salutaris Medical Devices, Inc (SalutarisMD) SalutarisMD is a pre-revenue medical device company founded to engineer a novel ophthalmic treatment for Wet age-related Macular Degeneration (Wet AMD). We have developed a minimally invasive procedure to provide improved outcomes for the million of patients afflicted with Wet AMD. Our patented and patent pending technology delivers a single-use brachytherapy (radiation) procedure that can be performed in an outpatient setting in approximately 15 minutes. The SalutarisMD device is a practical, clinic-based procedure designed to provide precise lesion-specific targeting. The procedure is performed using a hand-held instrument under the direct care and expertise of the treating retina specialist to deliver localized tissue irradiation, customized for each patient. About Wet Age-related Macular Degeneration Wet Age-related Macular Degeneration is a leading cause of vision loss worldwide. Wet AMD primarily affects the elderly, who represent an increasingly larger proportion of the industrialized worlds population. Annually, <500,000 new cases of Wet AMD are diagnosed in North America and Europe. Ultimately the Asian market will be the largest. According to a study from investigators at Yamagata University Faculty of Medicine, Japan, and others, Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations. Wet AMD is currently a >$8 Billion therapeutic market. The disease is currently treated by chronic, expensive pharmaceuticals (e.g., anti-VEGF drugs Lucentis and Avastin from Genentech/Roche and Eylea from Regeneron/Bayer) that only restore vision in 34%-40% of patients. These available treatment regimens are costly, burdensome and there is a large unmet need for more effective therapies.


Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access